Yuan-Lin Guo

List of Publications by Year
in descending order

136 papers	2,563 citations	257450 24 h-index	315739 38 g-index
137 all docs	137 docs citations	137 times ranked	2804 citing authors

#	Article	IF	Citations
1	NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. Lipids in Health and Disease, 2022, 21, 3.	3.0	5
2	Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies. Metabolism: Clinical and Experimental, 2022, 127, 154960.	3.4	13
3	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2022, 9, 797297.	2.4	1
4	Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease. Frontiers in Endocrinology, 2022, 13, 860698.	3.5	0
5	SORBS2 as a molecular target for atherosclerosis in patients with familial hypercholesterolemia. Journal of Translational Medicine, 2022, 20, 233.	4.4	2
6	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. Thrombosis and Haemostasis, 2021, 121, 1161-1168.	3.4	12
7	Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study. BMJ Open, 2021, 11, e037340.	1.9	2
8	Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: A prospective cohort study. Liver International, 2021, 41, 1294-1304.	3.9	12
9	Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatology International, 2021, 15, 413-423.	4.2	27
10	Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2021, , .	1.8	11
11	The difference between fasting and non-fasting lipid measurements is not related to statin treatment. Annals of Translational Medicine, 2021, 9, 386-386.	1.7	8
12	Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study. Cardiovascular Diabetology, 2021, 20, 84.	6.8	17
13	Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia. Annals of Translational Medicine, 2021, 9, 556-556.	1.7	0
14	Lipoprotein (a), hypertension, and cardiovascular outcomes: a prospective study of patients with stable coronary artery disease. Hypertension Research, 2021, 44, 1158-1167.	2.7	10
15	Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status. Atherosclerosis, 2021, 330, 29-35.	0.8	9
16	Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway. Annals of Translational Medicine, 2021, 9, 1517-1517.	1.7	20
17	Association of diabetes mellitus with clinical outcomes in patients with different coronary artery stenosis. Cardiovascular Diabetology, 2021, 20, 214.	6.8	8
18	Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study. Hepatology International, 2021, 15, 1337-1346.	4.2	15

#	Article	IF	Citations
19	Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: a population-based study. The Lancet Regional Health - Western Pacific, 2021, 17, 100286.	2.9	6
20	Association of small dense LDL-cholesterol with disease severity, hypertension status and clinical outcome in patients with coronary artery disease. Journal of Hypertension, 2021, 39, 511-518.	0.5	9
21	Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. Thrombosis Journal, 2021, 19, 90.	2.1	5
22	Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia. Journal of Translational Medicine, 2021, 19, 498.	4.4	5
23	Lipoprotein(a) Is Associated with the Presence and Severity of New-Onset Coronary Artery Disease in Postmenopausal Women. Journal of Women's Health, 2020, 29, 503-510.	3.3	7
24	Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia. Journal of Clinical Laboratory Analysis, 2020, 34, e23161.	2.1	7
25	Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study. Journal of Translational Medicine, 2020, 18, 373.	4.4	9
26	Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 167.	6.8	25
27	Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes. Cardiovascular Diabetology, 2020, 19, 152.	6.8	9
28	Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus. BMC Endocrine Disorders, 2020, 20, 156.	2.2	18
29	The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry. Frontiers in Cardiovascular Medicine, 2020, 7, 113.	2.4	4
30	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. Journal of Lipid Research, 2020, 61, 1254-1262.	4.2	25
31	Differential leukocyte counts and cardiovascular mortality in very old patients with acute myocardial infarction: a Chinese cohort study. BMC Cardiovascular Disorders, 2020, 20, 465.	1.7	10
32	Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis. Current Medical Science, 2020, 40, 879-884.	1.8	9
33	Heart-type fatty acid binding protein predicts cardiovascular events in patients with stable coronary artery disease: a prospective cohort study. Annals of Translational Medicine, 2020, 8, 1349-1349.	1.7	8
34	Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart, 2020, 106, 1228-1235.	2.9	28
35	Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a. Journal of Translational Medicine, 2020, 18, 195.	4.4	22
36	Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. Cardiovascular Diabetology, 2020, 19, 36.	6.8	24

#	Article	IF	Citations
37	The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. Cardiovascular Diabetology, 2020, 19, 104.	6.8	42
38	Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 111.	6.8	24
39	Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study. Cardiovascular Diabetology, 2020, 19, 15.	6.8	10
40	Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 45.	6.8	44
41	Association of serum lipoprotein(a) level with the severity and prognosis of calcific aortic valve stenosis: a Chinese cohort study. Journal of Geriatric Cardiology, 2020, 17, 133-140.	0.2	4
42	Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study. Heart Lung and Circulation, 2019, 28, 1009-1017.	0.4	13
43	A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia. Clinical Cardiology, 2019, 42, 988-994.	1.8	7
44	Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease. Prostaglandins and Other Lipid Mediators, 2019, 144, 106345.	1.9	9
45	Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status. Cardiovascular Diabetology, 2019, 18, 134.	6.8	20
46	Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia. Atherosclerosis, 2019, 291, 27-33.	0.8	13
47	Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia. Personalized Medicine, 2019, 16, 467-478.	1.5	1
48	Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. Journal of Translational Medicine, 2019, 17, 367.	4.4	20
49	Free fatty acids as a marker for predicting periprocedural myocardial injury after coronary intervention. Postgraduate Medical Journal, 2019, 95, 18-22.	1.8	6
50	High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. Hypertension Research, 2019, 42, 1783-1793.	2.7	14
51	A Novel Modified System of Simplified Chinese Criteria for Familial Hypercholesterolemia (SCCFH). Molecular Diagnosis and Therapy, 2019, 23, 547-553.	3.8	9
52	Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes. Diabetes Care, 2019, 42, 1312-1318.	8.6	82
53	Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case–Control Study. Clinical and Translational Gastroenterology, 2019, 10, e00011.	2.5	18
54	Severe aortic valve stenosis in a 14-year-old boy with sitosterolemia. Journal of Clinical Lipidology, 2019, 13, 49-53.	1.5	11

#	Article	IF	Citations
55	Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes. Hypertension, 2018, 71, 1039-1046.	2.7	68
56	Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia. Journal of Clinical Laboratory Analysis, 2018, 32, e22442.	2.1	15
57	Impact of glucose and lipid markers on the correlation of calculated and enzymatic measured low‐density lipoprotein cholesterol in diabetic patients with coronary artery disease. Journal of Clinical Laboratory Analysis, 2018, 32, e22399.	2.1	3
58	Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans. Chronic Diseases and Translational Medicine, 2018, 4, 117-126.	1.2	4
59	Predictive value of big endothelin-1 on outcomes in patients with myocardial infarction younger than 35 years old. Personalized Medicine, 2018, 15, 25-33.	1.5	4
60	Association between plasma proprotein convertase subtisilin/kexin type 9 concentration and coronary artery calcification. Annals of Clinical Biochemistry, 2018, 55, 158-164.	1.6	19
61	Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case‐control study. Metabolism: Clinical and Experimental, 2018, 79, 33-41.	3.4	18
62	Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. Journal of Thoracic Disease, 2018, 10, 6137-6146.	1.4	122
63	Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation. Lipids in Health and Disease, 2018, 17, 252.	3.0	19
64	Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids in Health and Disease, 2018, 17, 265.	3.0	18
65	Intensive genetic analysis for Chinese patients with very high triglyceride levels: Relations of mutations to triglyceride levels and acute pancreatitis. EBioMedicine, 2018, 38, 171-177.	6.1	22
66	Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease. Journal of Translational Medicine, 2018, 16, 345.	4.4	27
67	Oxidized-LDL is a useful marker for predicting the very early coronary artery disease and cardiovascular outcomes. Personalized Medicine, 2018, 15, 521-529.	1.5	9
68	Triglyceride glucose and haemoglobin glycation index for predicting outcomes in diabetes patients with new-onset, stable coronary artery disease: a nested case-control study. Annals of Medicine, 2018, 50, 576-586.	3.8	61
69	Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovascular Diabetology, 2018, 17, 48.	6.8	33
70	Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study. Biomarkers, 2018, 23, 647-653.	1.9	20
71	The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia. Atherosclerosis, 2018, 277, 7-14.	0.8	22
72	Familial hypercholesterolemia in very young myocardial infarction. Scientific Reports, 2018, 8, 8861.	3.3	14

#	Article	IF	Citations
73	ApoB is superior to LDL-C or non-HDL-C as a lipid marker for predicting the presence and severity of atherosclerosis in female patients with myocardial infarction. Hellenic Journal of Cardiology, 2017, 58, 223-225.	1.0	2
74	Plasma big endothelin-1 levels at admission and future cardiovascular outcomes: A cohort study in patients with stable coronary artery disease. International Journal of Cardiology, 2017, 230, 76-79.	1.7	29
75	Plasma free fatty acids in relation with the severity of coronary artery disease in non-diabetics: A Gensini score assessment. IJC Metabolic & Endocrine, 2017, 14, 48-52.	0.5	10
76	Remnant cholesterol predicts periprocedural myocardial injury following percutaneous coronary intervention in poorly-controlled type 2 diabetes. Journal of Cardiology, 2017, 70, 113-120.	1.9	11
77	Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular Events in Diabetics With Coronary Artery Disease. American Journal of the Medical Sciences, 2017, 354, 117-124.	1.1	43
78	Distribution of ABO Blood Groups and Coronary Artery Calcium. Heart Lung and Circulation, 2017, 26, 593-598.	0.4	5
79	Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study. BMJ Open, 2017, 7, e015041.	1.9	28
80	High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients withÂstable coronary artery disease. Atherosclerosis, 2017, 263, 104-111.	0.8	7
81	Homozygous familiar hypercholesterolemia in China: Case series from the national lipid clinics and literature review. IJC Metabolic & Endocrine, 2017, 14, 75-80.	0.5	1
82	Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. Scientific Reports, 2017, 7, 360.	3.3	22
83	Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis, 2017, 260, 67-74.	0.8	65
84	Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 570-579.	2.4	49
85	Analysis of Lipoprotein Subfractions in 920 Patients With and Without Type 2 Diabetes. Heart Lung and Circulation, 2017, 26, 211-218.	0.4	12
86	Elevated resting heart rate is associated with the severity of coronary artery disease in non-treated patients who underwent coronary angiography: potential role of lipoprotein subfractions. Archives of Physiology and Biochemistry, 2017, 123, 356-363.	2.1	7
87	Free fatty acids and cardiovascular outcome: a Chinese cohort study on stable coronary artery disease. Nutrition and Metabolism, 2017, 14, 41.	3.0	18
88	Big endothelin-1 level is a useful marker for predicting the presence of isolated coronary artery ectasia. Biomarkers, 2017, 22, 331-336.	1.9	7
89	Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Oncotarget, 2017, 8, 12333-12341.	1.8	8
90	Association between fibrinogen level and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old. Oncotarget, 2017, 8, 81361-81368.	1.8	15

#	Article	IF	Citations
91	Positive correlation of plasma PCSK9 levels with HbA$_{1c}$ in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 193-199.	4.0	36
92	Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima–media thickness in hypertensives. Hypertension Research, 2016, 39, 598-605.	2.7	13
93	Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Annals of Medicine, 2016, 48, 305-312.	3.8	44
94	Plasma d-Dimer as a Useful Marker Predicts Severity of Atherosclerotic Lesion and Short-Term Outcome in Patients With Coronary Artery Disease. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 633-640.	1.7	17
95	Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C. Heart Lung and Circulation, 2016, 25, 975-981.	0.4	43
96	Enhanced pro–protein convertase subtilisin/kexin type 9 expression by C–reactive protein through p38 MAPK–HNF 1α pathway in HepG2 cells. Journal of Cellular and Molecular Medicine, 2016, 20, 2374-2383.	3.6	21
97	HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort. Scientific Reports, 2016, 6, 30741.	3.3	17
98	Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study. Journal of Clinical Lipidology, 2016, 10, 1344-1352.	1.5	32
99	Apoprotein C-III: A review of its clinical implications. Clinica Chimica Acta, 2016, 460, 50-54.	1.1	18
100	Short- and long-term effects of Xuezhikang (è¡€è„‚åº·), an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels. Chinese Journal of Integrative Medicine, 2016, 22, 96-100.	1.6	12
101	Fibrinogen and the Severity of Coronary Atherosclerosis among Adults with and without Statin Treatment: Lipid as a mediator. Heart Lung and Circulation, 2016, 25, 558-567.	0.4	8
102	Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease. Journal of Diabetes and Its Complications, 2016, 30, 115-120.	2.3	7
103	C-reactive protein as a predictor for poor collateral circulation in patients with chronic stable coronary heart disease. Annals of Medicine, 2016, 48, 83-88.	3.8	10
104	Effects of Hedan Tablet (è•ä¸¹ç‰‡) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study. Chinese Journal of Integrative Medicine, 2016, 22, 660-665.	1.6	5
105	Relationship of lipid and lipoprotein ratios with coronary severity in patients with new on-set coronary artery disease complicated with type 2 diabetics. Journal of Geriatric Cardiology, 2016, 13, 685-692.	0.2	8
106	Free triiodothyronine in relation to coronary severity at different ages: Gensini score assessment in 4206 euthyroid patients. Journal of Geriatric Cardiology, 2016, 13, 978-983.	0.2	7
107	Lipid profiles in nontreated Chinese patients with stable coronary artery disease: a cross-sectional study. Clinical Lipidology, 2015, 10, 369-378.	0.4	1
108	Association of Big Endothelin-1 with Coronary Artery Calcification. PLoS ONE, 2015, 10, e0142458.	2.5	15

#	Article	IF	Citations
109	Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	9
110	ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 411-417.	2.6	17
111	High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. Journal of Clinical Lipidology, 2015, 9, 26-34.	1.5	48
112	Lipoprotein subfractions partly mediate the association between serum uric acid and coronary artery disease. Clinica Chimica Acta, 2015, 441, 109-114.	1.1	16
113	Thyroid function and PCSK9 in euthyroid subjects with coronary artery disease. Clinical Lipidology, 2015, 10, 235-242.	0.4	2
114	Relationship of High‐Density Lipoprotein Cholesterol With Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention in Patients With Low‐Density Lipoprotein Cholesterol Below 70 mg/dL. Journal of the American Heart Association, 2015, 4, e001412.	3.7	18
115	Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease. Clinica Chimica Acta, 2015, 446, 195-200.	1.1	7
116	Analysis of Lipoprotein Subfractions in Chinese Han Patients with Stable Coronary Artery Disease. Heart Lung and Circulation, 2015, 24, 1203-1210.	0.4	16
117	Circulating non–HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease. Journal of Clinical Lipidology, 2015, 9, 794-800.	1.5	18
118	Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation. Diabetes and Vascular Disease Research, 2015, 12, 258-264.	2.0	21
119	Relationship of Glycated Hemoglobin Levels with Myocardial Injury following Elective Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2014, 9, e101719.	2.5	6
120	Higher Fibrinogen Level is Independently Linked with the Presence and Severity of New-Onset Coronary Atherosclerosis among Han Chinese Population. PLoS ONE, 2014, 9, e113460.	2.5	30
121	Association of Fibrinogen with Severity of Stable Coronary Artery Disease in Patients with Type 2 Diabetic Mellitus. Disease Markers, 2014, 2014, 1-8.	1.3	22
122	Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-8.	1.2	12
123	Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. Journal of Clinical Lipidology, 2014, 8, 423-432.	1.5	12
124	Relation of ABO blood groups to the severity of coronary atherosclerosis: An Gensini score assessment. Atherosclerosis, 2014, 237, 748-753.	0.8	46
125	High-sensitivity C-reactive protein mediates in part the impact of ABO blood group on coronary artery disease. International Journal of Cardiology, 2014, 177, 641-643.	1.7	10
126	Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes. Atherosclerosis, 2014, 237, 536-543.	0.8	15

#	Article	IF	Citations
127	Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. Journal of Clinical Lipidology, 2014, 8, 494-500.	1.5	68
128	PCSK9 and lipid lowering drugs. Clinica Chimica Acta, 2014, 437, 66-71.	1.1	32
129	Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis, 2014, 234, 441-445.	0.8	96
130	Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. International Journal of Cardiology, 2014, 174, 863-864.	1.7	39
131	Relation of Leukocytes and Its Subsets Counts with the Severity of Stable Coronary Artery Disease in Patients with Diabetic Mellitus. PLoS ONE, 2014, 9, e90663.	2.5	18
132	Clinical features of coronary artery ectasia in the elderly. Journal of Geriatric Cardiology, 2014, 11, 185-91.	0.2	2
133	Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9. Clinical Drug Investigation, 2013, 33, 877-883.	2.2	46
134	Evaluation of Red Blood Cell Distribution Width in Patients with Cardiac Syndrome X. Disease Markers, 2013, 34, 333-339.	1.3	9
135	Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing. Journal of Geriatric Cardiology, 2013, 10, 361-8.	0.2	16
136	Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration. World Journal of Cardiology, 2010, 2, 160.	1.5	12